首页   按字顺浏览 期刊浏览 卷期浏览 Treatment of Thrombotic Disorders in Cancer Patients
Treatment of Thrombotic Disorders in Cancer Patients

 

作者: M. Levine,  

 

期刊: Pathophysiology of Haemostasis and Thrombosis  (Karger Available online 1997)
卷期: Volume 27, issue 1  

页码: 38-43

 

ISSN:1424-8832

 

年代: 1997

 

DOI:10.1159/000217481

 

出版商: S. Karger AG

 

关键词: Cancer;Low-molecular-weight heparin;Thrombosis

 

数据来源: Karger

 

摘要:

Cancer patients are in a hypercoagulable state. The pathogenesis of thrombosis in malignancy is multifactorial with mechanisms including release of procoagulants by tumour cells, comorbid predisposing factors (bed rest, infection, surgery, etc.) and anti-cancer drugs. Cancer patients with established venous thromboembolism are more likely to develop recurrent venous thromboembolism during treatment with oral anticoagulants. This paper reviews the use of heparin for the treatment of thrombotic disorders in cancer patients. Treatment of acute venous thrombosis comprises initial heparin administration, which for a cancer patient should last for at least 5 days, followed by administration of oral anticoagulants. Low-molecular-weight heparins (LMWHs) have been shown to be as safe and effective as standard heparin for the treatment of acute deep vein thrombosis. Recent meta-analyses have revealed lower mortality rates with LMWH than with standard heparin, indicating that LMWH may exert an inhibitory effect on tumour growth that is not observed with standard heparin.

 

点击下载:  PDF (2257KB)



返 回